11/14
09:49 am
tovx
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]
Low
Report
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]
11/12
08:37 am
tovx
Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]
Medium
Report
Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]
11/12
08:00 am
tovx
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
High
Report
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
10/31
04:05 pm
tovx
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
High
Report
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
10/16
08:00 am
tovx
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
Medium
Report
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
10/3
09:17 am
tovx
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]
Medium
Report
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]
10/3
08:00 am
tovx
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
High
Report
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
9/26
09:06 pm
tovx
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
High
Report
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
9/23
08:00 am
tovx
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
High
Report
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
9/16
08:00 am
tovx
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program
Low
Report
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program
8/23
11:50 am
tovx
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033 [Yahoo! Finance]
Low
Report
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033 [Yahoo! Finance]